SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2023.
Commission File Number: 001-40852
(Translation of registrants name into English)
c/o Ocorian Trust (Cayman) Limited
PO Box 1350, Windward 3, Regatta Office Park
Grand Cayman KY1-1108
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
On March 7, 2023, LumiraDx Limited began using an updated corporate presentation at investor presentations, a copy of which is attached hereto as Exhibit 99.1. The fact that this presentation is being made available and filed herewith is not an admission as to the materiality of any information contained in the presentation.
|99.1||Investor presentation, dated March 2023, furnished herewith.|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: March 7, 2023|
/s/ Dorian LeBlanc
|Title:||Chief Financial Officer|
March 2023 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Disclaimer FORWARD-LOOKING STATEMENTS All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements may generally be identified by the use of words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, project, forecast, predict, potential, seem, seek, future, outlook, target or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics, projections of market opportunity and market share, our future results of operations and financial position, business strategy, the Platform, other products, tests, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of LumiraDx Limited (LumiraDx or the Company) and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions, and such differences may be material. Many actual events and circumstances are beyond the control of LumiraDx. These forward-looking statements are subject to a number of risks and uncertainties, including our ability to compete in the highly competitive markets in which we operate, and potential adverse effects of this competition; our ability to maintain revenues if our products and services do not achieve and maintain broad market acceptance, or if we are unable to keep pace or adapt to rapidly changing technology, evolving industry standards and changing regulatory environments; uncertainty, downturns and changes in the markets we serve; our expectations regarding the size of the POC market for the Platform, the size of the various addressable markets for certain tests and our ability to penetrate such markets by driving the conversion of healthcare providers testing needs onto the Platform; our commercialization strategy, including our plans to initially focus our sales efforts on large healthcare systems, government organizations and national pharmacy chains that want to deploy comprehensive POC testing across their networks, our strategy on the commercialization of our current and future assays and our ability to launch and obtain regulatory approval for new tests; our ability to increase the installed base of our Instruments; our ability to repay or service our debt obligations and meet the financial covenants related to such debt obligations; our belief that we will be able to drive commercialization of the Platform through the launch of our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests; the willingness of healthcare providers to use a POC system over central lab systems and the rate of adoption of the Platform by healthcare providers and other users; the scalability and commercial viability of our manufacturing methods and processes, especially in light of the anticipated demand for the Platform and our minimum commitments to supply the Instrument and test strips in a timely fashion; our ability to maintain our current relationships, or enter into new relationships, with diagnostics or research and development companies, third party manufacturers and commercial distribution collaborators; our ability to effectively manage our anticipated growth; our ability to rapidly develop and commercialize diagnostics tests that are accurate and cost-effective; the timing, progress and results of our diagnostic tests, including statements regarding launch plans and commercialization plans for such tests, all which may be delayed by or halted due to a number of factors, including the impact of the COVID-19 pandemic and the end of the COVID-19 pandemic; the timing, scope or likelihood of regulatory submissions, filings, approvals, authorizations, certifications, clinical trials or clearances; the pricing, coverage and reimbursement of the Instrument and tests, if approved; our ability to enforce our intellectual property rights and to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties; developments and projections relating to our competitors and our industry; our ability to attract, motivate and retain qualified employees, including members of our senior management team; the effects of the COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business or operations; social, economic, and labor instability in the countries in which we or the third parties with whom we engage operate, including any impact of the current conflict between Russia and Ukraine; our expectations regarding the time during which we will be an emerging growth company under the JOBS Act and a foreign private issuer; the future trading price of our common shares and impact of securities analysts reports on these prices; our ability to fully derive anticipated benefits from existing or future acquisitions, joint ventures, investments or dispositions; exchange rate fluctuations and volatility in global currency markets; changes in interest rates, inflation rates and global and domestic market conditions; potential adverse tax consequences resulting from the international scope of our operations, corporate structure and financing structure; U.S. tax legislation enacted in 2017, which could materially adversely affect our financial condition, results of operations and cash flows; increased risks resulting from our international operations and expectations of future expansion of such operations; our ability to comply with various trade restrictions, such as sanctions and export controls, resulting from our international operations; government and agency demand for our products and services and our ability to comply with government contracting regulations; our ability to operate in a litigious environment; and those factors discussed under the header Risk Factors in the Annual Report on Form 20-F filed by LumiraDx with the Securities and Exchange Commission, or SEC, on April 13, 2022, in the Form 6-K filed by LumiraDx with the SEC on August 16, 2022, and in other filings made by LumiraDx with the SEC. If any of these risks materialize or LumiraDxs assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that LumiraDx presently knows or that LumiraDx currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect LumiraDxs expectations, plans or forecasts of future events and views as of the date of this presentation. LumiraDx anticipates that subsequent events and developments will cause LumiraDxs assessments to change. However, while LumiraDx may elect to update these forward-looking statements at some point in the future, LumiraDx specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing LumiraDxs assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. LumiraDx has no obligation to update this presentation. INDUSTRY AND MARKET DATA This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. LumiraDx believes that these third-party sources and estimates are reliable, but has not independently verified them. LumiraDxs estimates of the potential market opportunities for its Platform include several key assumptions based on industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While LumiraDx believes that its own internal assumptions are reasonable, no independent source has verified such assumptions. The industry in which LumiraDx operates is subject to a high degree of uncertainty and risk due to a variety of important factors that could cause results to differ materially from those expressed in the estimates made by third parties and by LumiraDx. 2
Financial Updates ? Continued progress on strategic discussions with industry partners to accelerate the business plan, with both additional capital and strategic collaborations under consideration. ? Modified debt agreement with senior lender to waive certain financial covenants until June 30, 2023, as strategic discussions progress: ? Form 6-K filed with the SEC on February 22, 2023? https://investors.lumiradx.com/node/7321/html 3
LumiraDx Today: Transforming Community-based Healthcare ? Next Generation POC(1) Addressing the current limitations of legacy POC systems by bringing lab-comparable performance Diagnostic Company to the POC in minutes, a broad menu of tests on a single instrument, and a low cost of ownership ? Large Installed Base with 25,000+ instruments shipped to 105 countries across primary care, pharmacy, hospital emergency lobal Commercial Reach departments, global health, and other settings ? Manufacturing All current and future POC tests are developed on common strip design, enabling flexible, automated and Designed for Scale low-cost manufacturing on a single line. Current manufacturing capacity of 28 million test strips per month ? Broad Menu and Pipeline (2) Regulatory clearance for 12 tests for use on our Platform, with global TAM of $5B+ (excluding COVID). of Diagnostic Tests 50+ assays in three-year roadmap ? Experienced Fourth POC company for founding team. Management team has a successful track record Management Team of diagnostic innovation and building / scaling companies in POC (1) POC means point of care. (2) Global Total Addressable Market (TAM): We estimate each test based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could 4 move to POC; and (c) expansion of diagnostic testing. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Healthcare Systems Need Enhanced Access to Diagnostic Testing Test Performed at Central Lab?Extended time to diagnosis and treatment selection Sample packed Sample shipped Lab processes Clinician receives Patient receives Results verified for transport to central lab sample results results?Significant logistic requirements Patient visits ?Higher cost to healthcare Point-of-care system Sample(s) (GP, collected Up to ~1 Week from Collection to Results Pharmacy, ER) ?Rapid delivery of results Test Performed at POC and diagnosis Sample Processed Patient receives ?Convenient and easily by POC instrument results accessible ?Allows immediate treatment decision (if required) Short time between Collection to Results ? Enables Faster and more Effective Care ?Significant cost efficiencies ?Improved patient experience 5
Leadership Team Management Experience Ron Zwanziger Dave Scott, Ph.D. Jerry McAleer, Ph.D. Nigel Lindner, Ph.D. (Founders) (Founders) (Founders) CEO, Co-Founder, Chief Technology Officer, Chief Scientist, Chief Innovation Chairman and Director Co-Founder and Director Co-Founder and Director Officer Tom Quinlan David Walton, D.M.S. Peter Scheu Veronique Ameye General Manager, Chief Commercial President, North American Deputy Chief Executive Health IT Officer Commercial Operations Officer and General Counsel Dorian LeBlanc, C.P.A. Pooja Pathak CFO and Vice President, Chief Product Officer Global Operations 6
Current POC Solutions Have Major Limitations The traditional approach to POC test development has limited scalability and has resulted in ineffective, inefficient and costly solutions Poor clinical performance in areas of high clinical need Respiratory Diabetes, Coagulation Immunoassay Inflammation High cost of total ownership Limited test menu Respiratory Diabetes, Cardiac, Blood Molecular Cardiovascular gas, Metabolic 7
We Have Developed and Commercialized an Innovative, Disruptive Solution for POC Testing Lab-comparable Consolidating multiple performance in minutes POC systems onto a single instrument, the LumiraDx Platform is Broad menu of tests designed to be a one-stop on a single instrument solution to transform diagnostic testing and health outcomes around the world Low cost of ownership 8 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
LumiraDx Platform Simplifies, Scales Down and Integrates Principles Used LumiraDx Platform Central Lab System Fluorescence / Common Transduction Fluorescence / electrochemical chemiluminescence Precise Fluidic Control Piezo bender / test strip bladder Syringe pumps No Sample Matrix Bias Gas wash / liquid-free image Multiple buffer washes Non-Specific Binding Particle coating / anti-hama Assay design / anti-hama Control Calibration Bias Calibration to lab standard Calibration to lab standard Assay Precision Materials, process, assay controls Chemistry, assay controls 9
Our Platform Allows for Multiple Sample Types and Test Technologies on Common Strip Architecture Test Technologies Immunoassay Clinical Chemistry Enzyme Hematology Molecular Electrolytes / Blood Gas Sample Types Fingerstick blood Nasal/Nasopharyngeal Throat Swab + Saliva Venous blood/ Urine Plasma/Serum 10
Simple, Common Strip Design Enables Low Cost and Disruptive Market Pricing Testing Prices* 5 10x Central Lab 2 3x Central Lab Base Price Central Lab LumiraDx POC Other POC * company estimate 11
High Sensitivity at POC Driven by Microfluidic Immunofluorescence Technology 8 Results Displayed Sample and Any Unbound 4 Sandwich Assay Binding Assay Binding View 6 Label Removed Using Air Sample Reagents and Actively Mixed Mag Particle Fluorescent Latex in Channels Mag Latex 3 Magnet RESULTS IN 2 MINUTES Move Active Sample Fluidics 1 Optical Reader Engine Sample Added Magnet Magnet 5 Magnetic Field Captures Bound Particles 7 Dry, Clear Fluorescent Signal Measured 12
We Have Launched a Broad Menu of Tests with Lab Comparable Performance Respiratory RNA STAR COVID RNA STAR COVID RNA STAR Complete COVID & Flu RNA STAR Complete TAM1 $12B $1.5-3B $200-400M $9B $12B / $12B / $1B Market2 US / EU / JP / BR EU EU / JP EU EU US / EU Coagulation Inflammation Diabetes Cardiovascular Area Legend \\\A Qualitative Immunoassay Quantitative Immunoassay Enzyme TAM1 $500M $700M $300M $1.3B $350M 2 Molecular Market EU EU EU EU EU (1) 2021 Global Total Addressable Market (TAM), based on our assumptions, including the (a) existing market sizes, (b) central lab market that could move to the POC, and (c) expansion of diagnostic testing. COVID TAMs difficult to estimate at present, may overlap with each other. 13 (2) Markets with regulatory authorization. Commercial launch of Amira on hold. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Highly Scalable Manufacturing Enables Global Growth Strategy ? Test strips manufactured on a common platform using a high volume, web-based, automated manufacturing process? Platform manufacturing facilities located in Alloa, Stirling and Glasgow, Scotland with total current capacity of over 28 million test strips per month with possibility to expand further? Instrument manufactured by Flextronics (a contract manufacturer) at its facility in Althofen, Austria 14 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Platform Strategy Focused on Improving and Expanding the POC Testing Experience 1 Raise the standard for POC testing performance, speed, access and experience 2 Consolidate multiple POC instruments to a single lab comparable platform 3 Develop comprehensive test menus by disease and care setting 15 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Raise the Standard for POC Testing Performance, Speed, Access and Experience Example: Rule of Venous Thromboembolism with LumiraDx D-Dimer test ? High sensitivity and speed: ULTRA product line delivers high sensitivity results for respiratory disease diagnosis, taking test times from 15-30 minutes down to 5 minutes? Easy sample collection: Only quantitative fingerstick blood-based tests for D-Dimer and NT-proBNP to aid faster clinical decisions in community settings ? Built to expand access: Portable system (2.2 lbs, low footprint, battery operated, room temp reagents) ? 100% negative predictive value at the 500 ?g/L cut off, when and cloud-based connectivity enables centrally used in combination with a pretest probability score managed program in the community ? Fingerstick sample, results in 6 minutes ? Strong correlation with the laboratory reference, in particular around the clinically relevant values of <750 ?g/L FEU 16 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
LumiraDx NT-proBNP ? Sample type: Direct Fingerstick* No need for phlebotomy only direct fingerstick NT-proBNP test commercially available today ? Time to result: 12 minutes? Storage at room temperature ? Strong correlation to gold standard lab system, r=0.97 (Roche cobas Elecsys® proBNP II assay) The innovative LumiraDx NT-proBNP test can transform the diagnosis of heart failure by bringing the first true point of care NT-proBNP test to the community. *venous blood and plasma also validated Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
LumiraDx Roche h232 Quidel Triage Boditech iChroma Time to Result 12 mins 12 mins 20 mins 12 mins Sample type Fingerstick capillary, Venous whole blood Venous whole blood, Venous whole blood, Venous whole blood, plasma serum, plasma Measuring Range 50-9,000 pg/ml* 60-9,000 pg/ml 20-35,000 pg/ml 10-30,000 pg/ml Intended Use Aid in diagnosis Aid in Aid in the diagnosis and Aid in diagnosis, monitoring risk stratification and risk stratification Menu INR, CRP, D-Dimer, Flu, TnT, D-dimer, CK-MB, D-dimer, BNP, TnI, D-dimer, hsCRP, TnI, RSV, COVID,HbA1c, Myoglobin Toxicology panel, PLGF, Myoglobin, CK-MB, BNP, Myoglobin, CK-MB ST2 Storage Room temperature Refrigerated Registrations CE (BNP test is FDA CE CLIA waived) *To be extended to 35,000 pg/ml All third-party product, company names and logos are trademarks or registered® trademarks and remain the property of their respective holders. Use of them does not imply any affiliation with or endorsement by them. Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Unmet Need for High Sensitivity Troponin POC Test with a ~$900M Addressable Market(1) Lab Reference POC Example POC Example True POC Needs Abbott Architect STAT hs- Siemens Atellica VTLi hs- (2) (2) (2) Triage True hsTnI TnI cTnI Intended Use Aids in diagnosis of MI Aids in diagnosis of MI Aids in diagnosis of MI Aids in diagnosis of MI Regulatory CE Mark, FDA 510K CE Mark, FDA 510K CE Mark CE Mark Authorization ?3.2 ng/L (specification) 2.1 ng/L plasma 2.1-3.6 ng/L plasma LOQ ? 2.0 ng/L 1.5 2.9 ng/L (observed) 3.7 ng/L WB 2.8 ng/L WB Clinical Sensitivity Whole blood (2h): 90%+ EDTA Plasma (2-4h): 90.9% Whole blood (2h): 81.3% EDTA Plasma (2-4h): 91.9% 2.1 (plasma)/3.7 (WB) 1,250 Reportable Range 2.0 1,000 ng/L 3.2 50,000 ng/L 0.1 1,000 ng/L ng/L 210 µL (on-board) Sample Size 20µL direct fingerstick 30-100 µL 175 µL 10 µL (manual dilution) Capillary WB, venous Capillary WB, venous WB & Venous WB & plasma Sample Type Plasma & serum (LiHep, EDTA) blood, plasma plasma (LiHep) (EDTA) Time to Result ?10 min 18 min (time to first result) 8 min 20 min (1) Based on our current assumptions, including (a) the existing market sizes, (b) central lab market that could move to POC; and (c) expansion of diagnostic testing. 19 (2) Based on respective company product specifications. Key differentiator Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Feasibility of High Sensitivity Troponin Results at POC LumiraDx Plasma Troponin vs Architect 16.0 y = 0.9544x + 0.0377 R² = 0.9868 14.0 12.0 (pg/mL) 10.0 Precision Troponin 8.0 6.0 LumiraDx 4.0 2.0 0.0 0 2 4 6 8 10 12 14 16 -2.0 Mean Architect Troponin (pg/mL) 20
Strep A Molecular Program Demonstrates Feasibility to Achieve Target Sensitivity Key Targets and Workflow 98% sensitivity No culture confirmation Results in 8 minutes, with early call out starting 3 minutes Sample Collection & Lysis Insert Strip & Add Sample Amplification Performance Feasibility LMDX On market Dilution qSTAR POC MDX D1 (1:20) D2 (1:200) D3 (1:2000) D4 (1:20000) D1 (1:101) 8/8 3/3 D2 (1:102) 8/8 3/3 Group A Strep Group A Strep Group A Strep Group A Strep D3 (1:103) 8/8 3/3 D4 (1:104) 8/8 2/3 D5 (1:105) 0/8 0/3 D6 (1:106) 0/8 0/3 D7 (1:107) 0/8 0/3 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
TB Molecular Program Demonstrates Feasibility to Develop Swab Based POC Test Key Targets and Workflow Value Proposition ? Tongue swab sample POC TB test has opportunity to increase patients linked to care ? Results in 20 minutes? Access to testing for HIV+ and pediatric populations, currently underserved Performance Feasibility Copy No of number % positivity positives (cp/rxn) 11 8/8 100 5.6 8/8 100 1.3 33/38 87 0.6 3/8 33 TB Care Cascade in Indian Public Health System Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
LumiraDx Platform Offers the Benefits of POC Testing with the Accuracy of Laboratory Testing Prep Sample Load & Run Report Results Diagnosis and Treatment Selection 1 Minute 2 12 Minutes ? LumiraDx solutions combine common assay types all in one instrument (IA, clin chem, molecular, and enzyme); reduce costs and simplify workflow? A single scalable platform to complete a wide range of popular POC tests? Patient receives accurate results in minutes? Low-cost of ownership 23 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Consolidate Multiple POC Instruments to a Single Lab Comparable Platform x x x Respiratory Diabetes, Respiratory Diabetes, Cardiac, Blood gas, Coagulation Cardiovascular Metabolic Immunoassay Inflammation Molecular NEAR TERM 18-24 MONTHS Able to move most European customers from Expect to be able to move most US and 3 ? 1 Platform with INR, COVID Ag, Flu A/B, European customers RSV, CRP and HbA1c 6 ? 1 Platform with US authorizations and addition of molecular respiratory, lipids, electrolytes, and cardiac content 24 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Menu Expansion Leading to New Customer Case Study Acquisition and Higher Volume per Customer Germany, Austria and Switzerland (DACH) DACH COVID only vs. Multi-Assay Customers Number of Assays Shipped to Customer 400 Customers with 3+ assays grew from 3% in Dec 2021 Total customers grew from 108 customers in to 23% in Dec 2022 350 Dec 2021 to 365 customers in Dec 2022 300 250 200 150 100 50 0 Dec 2021 Mar 2022 Jun-22 Sep-22 Dec-22 1 2 3 4+ Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Innovation and Growth in High Sensitivity Respiratory Antigen Testing Respiratory Revenue Distribution Launch timelines Top 3 Countries Italy, UK, Japan COVID Ag CE Mark in Aug 2020 100% 90% COVID Ag PMDA (Japan) in Jan 2021 80% 70% COVID Ag Pool CE Mark in Jun 2021 60% COVID & Flu CE Mark in Dec 2021 50% 40% COVID & Flu PMDA (Japan) in Mar 30% 2022 20% COVID Ag Ultra and COVID Ag Ultra 10% 0% Pool CE Mark in May 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 COVID Ag COVID Ag Pool COVID Ag Ultra COVID Ag Ultra Pool COVID & Flu Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
COVID POC Testing Infrastructure Being Case Study Redeployed to Strengthen Community Based Care Virtual Wards CRP, D-Dimer testing to keep COPD patients out of the hospital ED Emergency Department Emergency Department COVID Testing Hubs D-Dimer testing for fast, accurate rule out of Outpatient UKHSA Pulmonary Embolism and Deep Vein Thrombosis Departments procured Elective and 1500 Emergency Surgery Instruments Admissions Cardiology Department Hospital Discharge NT-proBNP testing for fast, accurate diagnosis of acute coronary syndrome and heart failure Community Diagnostic Centers D-Dimer, NTproBNP testing in community to reduce ED referrals and congestion Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Knowsley Community Respiratory Service Case Study Patient Case Study 65-year-old male medical history of COPD and hypertensionContacted the Rapid Response Service complaining of a 3-day history of acute respiratory symptomsDenied breathlessness, complained of increased chesty cough, expectorating some watery yellow sputumNo chest or pleuritic pain, no haemoptysis, no peripheral oedema, NEWS early warning score = 0a low risk patient. Chest examination scattered crackles to bilateral lower zonesAlso complaining of congested nose and throat, query if this was a viral illnessLumiraDx CRP Test performed 124mg/L so patient provided 5-day course of amoxicillinFollow up visit patient has not felt improvement and sputum now dark greenLumiraDx CRP Test performed 160mg/L change in antibiotic therapy and provided 5-day course of doxycyclineFurther home visit 2 days after commencing doxycycline. LumiraDx CRP Test performed 45mg/L and overall improvement Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Develop Comprehensive Test Menus By Disease and Care Setting * Items marked in bold are the diagnostic tests for which we have obtained regulatory approval, authorization, certification or clearance for use on our Platform. 29 Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Appendix Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Point of Care Testing is Being Adopted Worldwide Western World Adoption: A Push Towards Community Care Global Health Adoption of POCT(3) United States POCT improves patient care, especially in re-source limited settings where laboratory infrastructure is poor and patients predominantly live in rural settings? A push towards community-based services is at the top of Bidens healthcare agenda with $400bn in Medicaid funding to expand 1? UNAIDS launched the Diagnostics Access Initiative, to ensure access to home and community based services increased access to quality diagnosis so people with HIV can be United Kingdom: NHS is leading the path in Europe effectively linked to quality treatment services ? The WHO recognises the importance that quality-assured POCT year plan to move to a new service will play in the success of global health programs ? In 2019 the NHS outlined its five model for the NHS, setting out five changes required: ? A study assessing the impact of POCT in Global Health disease 1 Boost out of hospital care programs found that: 2 Redesign and reduce pressure on emergency hospital services POCT in HIV resulted in a 20 fold increased uptake and ? coverage and increased status and awareness from an average 3 Deliver more personalised care of 6% to 20% 4 Digitally enable primary and outpatient care ? In tuberculosis, a study found POCT in communities resulted 5 Local NHS organisations to focus on population health in a 49% increased detection rate of tuberculosis ? T upport this the NHS committed Ł13bn to community pharmacys confirming their future as an integral part of the NHS2 (1) White House Infrastructure Bill 2021 (2) NHS England Long Term Plan 2019 31 (3) Peter N. Fonjungo, Debrah I. Boeras, Clement Zeh, Heather Alexander, Bharat S. Parekh, John N. Nkengasong, Access and Quality of HIV-Related Point-of-Care Diagnostic Testing in Global Health Programs, Clinical Infectious Diseases Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.
Copyright © 2023 LumiraDx Ltd. All Rights Reserved, Worldwide.